As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Multiple Sclerosis Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 133 high prescribing neurologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Neurologists 32 22 18 15 16 15 15

Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Sales-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Drug forecast period 2012–21
Drugs profiled
  • Ampyra
  • Aubagio
  • Avonex
  • Betaseron
  • Copaxone
  • Extavia
  • Gilenya
  • Lemtrada
  • Rebif
  • Sativex
  • Tecfidera
  • Tysabri
  • Daclizumab
  • Laquinimod
  • Ocrelizumab
  • Plegridy


Key Findings

Injectable treatments, valued at $10.6bn in 2012, will increasingly be eschewed in favor of novel oral treatments such as Tecfidera, Gilenya, and Aubagio, on account of their superior efficacy and/or tolerability profiles, as well as improved convenience. By 2021, sales of oral multiple sclerosis therapies will total $7.6bn.

Tecfidera will become the dominant multiple sclerosis therapy as Biogen Idec translates its successes in the clinic into blockbuster revenues in the marketplace. Datamonitor Healthcare projects peak-year sales of $4.5bn over the 2012–21 period.


> Download your free sample > Contact us to find out more


Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726